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A framework for application of metabolic modeling
in yeast to predict the effects of nsSNV in human
orthologs
Hayley Dingerdissen1, Daniel S Weaver2, Peter D Karp2, Yang Pan1, Vahan Simonyan3 and Raja Mazumder1,4*
Abstract
Background: We have previously suggested a method for proteome wide analysis of variation at functional
residues wherein we identified the set of all human genes with nonsynonymous single nucleotide variation (nsSNV)
in the active site residue of the corresponding proteins. 34 of these proteins were shown to have a 1:1:1 enzyme:
pathway:reaction relationship, making these proteins ideal candidates for laboratory validation through creation and
observation of specific yeast active site knock-outs and downstream targeted metabolomics experiments. Here we
present the next step in the workflow toward using yeast metabolic modeling to predict human metabolic
behavior resulting from nsSNV.
Results: For the previously identified candidate proteins, we used the reciprocal best BLAST hits method followed
by manual alignment and pathway comparison to identify 6 human proteins with yeast orthologs which were
suitable for flux balance analysis (FBA). 5 of these proteins are known to be associated with diseases, including
ribose 5-phosphate isomerase deficiency, myopathy with lactic acidosis and sideroblastic anaemia, anemia due to
disorders of glutathione metabolism, and two porphyrias, and we suspect the sixth enzyme to have disease
associations which are not yet classified or understood based on the work described herein.
Conclusions: Preliminary findings using the Yeast 7.0 FBA model show lack of growth for only one enzyme,
but augmentation of the Yeast 7.0 biomass function to better simulate knockout of certain genes suggested
physiological relevance of variations in three additional proteins. Thus, we suggest the following four proteins for
laboratory validation: delta-aminolevulinic acid dehydratase, ferrochelatase, ribose-5 phosphate isomerase and
mitochondrial tyrosyl-tRNA synthetase. This study indicates that the predictive ability of this method will improve as
more advanced, comprehensive models are developed. Moreover, these findings will be useful in the development
of simple downstream biochemical or mass-spectrometric assays to corroborate these predictions and detect
presence of certain known nsSNVs with deleterious outcomes. Results may also be useful in predicting as yet
unknown outcomes of active site nsSNVs for enzymes that are not yet well classified or annotated.
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Background
An enyzme’s active site specificity is an important de-
terminant of functional catalysis. For this reason, if a
nonsynonymous single nucleotide variation (nsSNV)
occurs at the active site, thereby changing an active site
amino acid residue, it is highly likely that enzyme activity
will be lost or altered [1-7]. It follows that pathway activity
should also be affected, with a potential end result of
disease [8-10] or lethality.
In our previous paper [11] we used the SNVDis Tool
[12], part of the High-performance Integrated Virtual
Environment (HIVE) tools suite (accessed at hive.bio-
chemistry.gwu.edu) [13] to identify the entire set of 559
human proteins with nonsynonymous variation at an
active site residue resulting from a single nucleotide
variation. Pathway, substrate and product annotation was
manually retrieved from Kyoto Encyclopedia of Genes and
Genomes (KEGG) [14] for all possible proteins in the
dataset. To the best of our knowledge, a subset of 34 of
the original proteins had a 1 enzyme:1 pathway:1 sub-
strate/product set ratio, meaning these enzymes catalyze a
single reaction for a single set of substrates and products
and are currently annotated to participate in a single
pathway. While there may be possible interaction be-
tween specified metabolites and alternative enzymes,
the 1:1:1 relationship ensures no alternative metabolic
interaction with the specified enzymes, thus making them
suitable candidates for in vivo laboratory validation.
For this paper, we used the reciprocal best BLAST
hits method [15] to query the set of 559 human active
site nsSNV proteins against the yeast (Saccharomyces
cerevisiae) proteome and, conversely, the top yeast pro-
tein hits back against the human proteome. We then
checked for active site residue conservation and pathway/
substrate/enzyme conservation between the 113 identified
human-yeast orthologous pairs. We found 6 proteins
which satisfied all criteria, 5 of which had human dis-
ease associations including anemias, porphyrias and
others. The high incidence of dysfunction annotated
among these active-site-nsSNV-containing proteins re-
inforces the notion that mutations in the active site dis-
rupt normal enzyme and/or pathway activity. Although it
may seem intuitive that the active site modifications are to
blame for these disease associations, it is surprising to
note that the disease-related annotations are not currently
attributed to the active site variations for the 5 proteins in
question, but are assigned to other sequence variations or
causes.
Merely studying genomic variation may not be enough
to determine the effects of active site variation, however,
as one needs to examine the interactions and physio-
logical outcome within the context of the cell, organ, or
entire system [16]. Metabolic modeling is our attempt
to test the impact of active site variation in a more
meaningful way as such methods get more sophisticated.
To this end, we used the Yeast 7.0 flux balance analysis
(FBA) model [17] to predict the effects of deleting these 6
proteins, constructed with the relevant nsSNV active site
mutation, on the growth of yeast. Since several of these
proteins are involved in production of important metabo-
lites that are not contained within the Yeast 7.0 biomass
function, we repeated the analysis using a revised biomass
equation that incorporates the relevant metabolites. FBA
is an established mathematical and computational approach
for studying metabolic networks [18,19]. FBA modeling has
a number of biotech applications as it allows programmatic
prediction of a metabolic phenotype using in silico compu-
tations of reaction stoichiometry without using reaction
kinetics [20-22]. FBA results have been shown to correlate
well with experimental observations [23].
In the future, predictions given by this in silico cell
model can be subjected to laboratory validation using
yeast cultures with site-induced mutagenesis to alter the
proper active site residue and observe the outcomes with
respect to growth rate, substrate and product quantities,
byproduct generation and general viability. We reason
that the conservation of these protein sequences from
yeast to humans, in conjunction with conserved active
site residues and conserved pathway interplay, provides
strong evidence that similar outcomes are likely to result
from mutations in the human orthologs [24].
Our overarching goal is to better understand phenotypic
effects of nsSNVs on the active site of enzymes. Although
we use a small set of enzymes here to perform a prelimin-
ary proof of principle, this experiment lays the foundation
for a method of cellular modeling that will move toward
an “omics” approach with potential predictive ability.
Similar large-scale studies already demonstrate the utility
of this type of approach to predict metabolite concentra-
tions related to environmental conditions [25], enzyme
phosphorylation [26] and even whole gene deletion [27],
but to the best of our knowledge there is no such effort to
apply a metabolomics approach to the analysis of active-
site- nsSNV-containing proteins to yield predictive and/or
diagnostic information.
Results and discussion
The complete human and yeast proteomes, and all protein
subsets, available from UniProtKB/Swiss-Prot, provide
curated annotation information regarding both nsSNV
and active sites [28]. The dbSNP database [29] provides
additional information on variations and the Conserved
Domain Database (CDD) [30] provides additional informa-
tion on active sites. The SNVDis tool uses this information
to return an output table with all human proteins contain-
ing nonsynonymous substitutions at the active site.
Note here that we do not discriminate between het-
erozygous and homozygous nsSNVs because pertinent
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information is unavailable for the majority of human
variation data. Previous findings imply that most nsSNVs
in active sites are rare or heterozygous because they are
expected to be selected against and, therefore, unlikely to
be observed in a homozygous pair [31]. Studies of consan-
guineous families may prove a good source for detection
of homozygous active site nsSNVs in the future, but there
are currently few documented cases [32] of catalytic
homozygote variants. This is problematic as currently
available models assume the haploid condition of a
yeast cell. Results of reducing the flux to zero in such a
model cannot be easily generalized to a diploid, heterozy-
gous state unless known loss of function via haploinsuffi-
ciency or dominant negative phenotypes is established.
Although we cannot say with certainty that the variations
presented in this paper confer this phenotype, there is
literature evidencing the heterozygous loss of function
associated with active site mutations in a number of
mammalian genes including mouse DNA polymerase δ
[33], human DNA polymerase γ [34] and mammalian
11β-hydroxysteroid dehydrogenase type I [35]. Further-
more, the aforementioned murine study was extended
from studies of homologous mutations in haploid yeast.
Thus, while we cannot fully extend haploid modeling to
proteins in diploid organisms, we suggest that yeast
enzymes whose knockouts alter flux balance necessitate
further attention be given to their orthologous human
counterparts, for both homozygous and heterozygous var-
iations. Specifically, we propose that haploid models could
still provide quantitative value toward the development of
predictive assays for highly conserved pathways in cases
of true loss of function due to heterozygous mutation at
human active sites.
A proteome-wide search in SNVDis returns 559 unique
human proteins (Additional file 1: Table A1) with nsSNV
at the active site. Subsequent pathway analysis using
annotations from KEGG shows a subset of 34 proteins
(updated from previous publication to include two add-
itional proteins from the same set of 559 which were later
found to meet the criteria) with nsSNV at the active site
and a 1 enzyme:1 pathway:1 reaction relationship. Full
methods and discussion for these and other preliminary
results can be seen in the prior publication.
Reciprocal best BLAST hits method to identify human-yeast
ortholog pairs
To identify proteins from yeast (S. cerevisiae) orthologous
to the 559 active-site-nsSNV-containing human proteins,
the reciprocal best BLAST hits method was used. The se-
quences for the 559 active-site-nsSNV-containing human
proteins were extracted from UniProtKB/Swiss-Prot by
UniProt Accession and used as the query in a BLAST [36]
against the yeast proteome. Of the 559, 173 proteins have
no hits against the yeast proteome with E-value less than
0.0001 and 146 proteins have significant hits but are
deemed to be paralogous. Thus, 240 of the 559 human
proteins are considered to have a one-way best hit. These
240 best-hit yeast proteins were then used as the query in
a second BLAST against the entire human proteome. Of
these 240, 127 have a unidirectional best-match such that
the highest scoring yeast match from the human BLAST
against the yeast proteome has an alternative highest-
scoring human match when queried against the entire
human proteome. This leaves 113 proteins with active
site nsSNV to have a reciprocal best-match ortholog in
yeast (Table 1, full reciprocal best BLAST hits data can
be shown in Additional file 1: Table A2).
Identification of candidate enzymes for in vivo validation
To be considered ideal for laboratory validation, we want
to first limit our consideration to the proteins in Table 2
which have a simple 1 enzyme:1 pathway:1 reaction rela-
tionship relationship. This 1:1:1 ratio drastically limits
the possibility for an enzyme to affect or be affected by
multiple metabolites during laboratory experiments. Of
the 34 potential candidates, 11 had no best hit and 10
had a one-way best hit, leaving 11 proteins as potential
candidates with reciprocal best-match orthologs.
We must also consider the case when the product of
an enzymatic reaction can be synthesized by alternative
means. For this paper, we decided to consider these cases
due to literature supporting biochemical importance of
dysfunction despite multiple pathways to product.
Additionally, we want to ensure the variable site of
interest, the active site, is conserved across ortholog pairs.
If functional residues are not conserved, we cannot say
that experimental observations resulting from a variation
in a yeast enzyme is at all indicative of outcomes of vari-
ation in the corresponding human enzyme. This was
checked by manual examination of alignments (Figure 1).
The minimum requirement for active site conservation is
that the residue(s) annotated as the active site residue(s)
are identical across species, although many of the human-
yeast pairs have blocks of up 10 amino acids conserved
across species. 10 of the 11 ortholog pairs were conserved
at the active site.
We want to further limit wet-lab candidate enzymes to
those with no other orthologs or paralogs. Even though
the proteins under consideration at this point are recipro-
cal best-matches, proteins with closely related homologs
limit the confidence with which we can report results of
laboratory validation experiments. For example, if a hu-
man protein has a best match with a yeast protein which
has paralogs, we cannot be sure upon knockout of the en-
zyme that the paralogous proteins will not interfere in the
metabolism we are trying to assay. Exclusion of proteins
with orthologs and paralogs was performed by manually
examining alignments. This exclusion now reduces our list
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of potential candidates to 6. Table 3 lists the active site
residue and surrounding conserved residues for these 6
proteins.
Finally, we want to make sure the ortholog pairs are
involved in similar pathways. If a human protein has
diverged to act on different metabolites we again cannot
use its yeast ortholog as a model to understand effects of
variation in human proteins. Pathway information for the
human proteins was previously retrieved and summarized
in Table 2. Pathway information for the yeast proteins was
Table 1 Human proteins with active site nsSNV and their yeast ortholog match
Human protein Yeast ortholog Human protein Yeast ortholog Human protein Yeast ortholog
Q9GZR2 Q08237 Q9P2J9 Q12511 Q15067 P13711
P49247 Q12189 Q9BZP6 Q06350 Q96S44 P53323
Q9UBZ4 P38207 O60825 P32604 O95154 P42884
Q14410 P32190 O15305 P07283 P78368 P23292
P51659 Q02207 Q9UNI6 Q02256 Q6PI48 P15179
P20618 P23724 Q96RR4 P43637 Q13164 Q00772
Q96T52 P46972 Q9NUW8 P38319 P06744 P12709
P08397 P28789 P00480 P05150 P11498 P32327
P04424 P04076 Q6IA69 P38795 P05186 P11491
P40818 P32571 Q04760 P50107 Q8TF76 P32789
Q8IWW8 P10127 P36873 P32598 P29120 P13134
P37268 P29704 Q9P2K8 P15442 Q8IWX5 P23501
Q96G46 Q06053 Q96GX9 P47095 Q96DP5 P32785
P48637 Q08220 Q13332 P25044 Q9Y3E5 P34222
P09467 P09201 P12955 P43590 P25789 P23638
Q9UGM6 P04803 P06132 P32347 P60484 P53916
P78549 P31378 O75191 P42826 P49917 Q08387
O96017 P39009 Q9H3S4 P35202 P32320 Q06549
Q7L3T8 P39965 P06737 P06738 Q9NSY1 P53974
Q9NYY3 P32562 Q13907 P15496 O60942 Q01159
O43426 P50942 P49841 P38615 Q9UGP5 P25615
O95363 P08425 P36871 P37012 Q9BUP3 P40008
P34949 P29952 Q9UBZ9 P12689 P54098 P15801
Q7L211 P42840 Q9HBY8 P12688 Q9UJM8 P00175
P07741 P49435 P07902 P08431 Q8WUX2 P32656
P13716 P05373 Q9Y2L1 Q08162 Q14249 P08466
P48449 P38604 Q96C11 Q04585 Q5VTY9 Q08929
P49336 P39073 O14818 P40303 Q86YJ6 P16120
Q8IZ73 Q12362 O00743 P20604 P12081 P07263
Q69YN2 P53255 Q5T2R2 P18900 Q9UQB9 P38991
Q99447 P33412 P04180 P40345 O14734 P41903
P30793 P51601 Q9Y3Q0 P47161 P14550 P14065
Q9BV23 P53750 O43175 P40054 P08243 P49090
P56937 Q12452 P22830 P16622 Q86V88 P40081
Q16769 P43599 O95336 P38858 Q8IXB1 P40564
Q15386 P53119 Q969P6 P04786 Q9Y3B8 P54964
Q9Y2H1 P53894 Q9Y2Z4 P48527 P00813 P53909
Q9UI42 P38836 Q9Y6R4 P53599
This table lists the pool of 113 reciprocal best match human-yeast ortholog pairs, a subset from the original 559 proteins with active site nsSNV.
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Table 2 34 proteins with active site nsSNV with substrate/product/pathway relationships ideal for use in metabolomics
UniProtKB Normal Variation Position Substrate increased Substrate ID Product decreased Product ID
A2RTX5 t a 532 L-threonine CID: 6288 L-threonyl-tRNA SID: 5901
O43175 r c 236 3-phospho-D-glycerate CID: 439183 3-phosphonooxypyruvate CID: 105
O75891 p l 107 10-formyltetrahydrofolate CID: 122347 Tetrahydrofolate CID: 91443
O75908 h q 434 cholesterol CID: 5997 Cholesterol ester SID: 5537
O75936 h q 347 4-trimethylammoniobutanoate CID: 134 Carnitine CID: 85
O95336 r c 185 6-phospho-D-glucono-1,5-lactone CID: 439452 6-phospho-D-gluconate CID: 91493
O95363 q x 160 L-phenylalanine CID: 6140 L-phenylalanyl-tRNA(Phe) SID: 6321
O95479 r c 728 Beta-D-glucose 6-phosphate CID: 439427 6-phospho-D-gluconate CID: 91493
O95861 a v 221 PAPS CID: 10214 Adenylyl sulfate CID: 10238
P04180 s n 205 Phosphatidyl choline SID: 3457 2-lysolecithin SID: 6900
P09417 y c 150 Tetrahydrobiopterin CID: 44257 Dihydrobiopterin CID: 133246
P13716 r p 221 5-aminolevulinate CID: 137 Porphobilinogen CID: 1021
P22830 d g 383 Ferrous ion | protoporphyrin IX CID: 27284 | CID: 4971 Heme CID: 444097
P23109 h q 305 Adenylic acid CID: 6083 Ammonia | inosinic acid CID: 222 | CID: 8582
P23946 h r 66 Angiotensin I CID: 3081372 Angiotensin CID: 172198
P25092 t a 618 Guanosine 5'-triphosphate CID: 6830 Cyclic gmp CID: 24316
P42357 g s 165 L-histidine CID: 6274 Urocanic acid CID: 736715
P43251 a s 271 Biocytin CID: 440721 Biotin | L-lysine CID: 171548 |CID: 5962
P48637 r c 125 Glycine | gamma-glutamylcysteine CID: 750 | CID: 123938 Glutathione CID: 124886
P49247 d y 160 D-ribulose 5-phosphate CID: 439184 Ribose 5-phosphate CID: 439167
Q02127 t i 284 L-dihydroorotic acid CID: 439216 Orotic acid CID: 967
Q02809 r h 718 Protein lysine SID: 5259 Procollagen 5-hydroxy-L-lysine SID: 4433
Q16873 r k 104 Leukotriene A4 CID: 5280383 Leukotriene C4 CID: 5280493
Q3SY69 y x 127 10-formyltetrahydrofolate CID: 122347 Tetrahydrofolate CID: 91443
Q6PI48 r x 266 L-aspartic acid CID: 5960 L-aspartyl-tRNA(Asp) SID: 5893
Q8IVS2 s t 153 Malonyl-CoA CID: 10663 Malonyl-[acyl-carrier-protein] SID: 4431
Q8N5D6 y x 121 Globoside SID: 124490726 IV3GalNAca-Gb4Cer SID: 124490727
Q8TDQ7 p s 182 D-glucosamine phosphate CID: 440997 Beta-D-fructose 6-phosphate CID: 440641
Q96C23 r x 82 Alpha-D-glucose CID: 79025 Beta-D-glucose CID: 64689
Q96GX9 g r 47 S-methyl-5-thio-D-ribulose 1-phosphate CID: 174549 5-(methylthio)-2,3-dioxopenyl phosphate CID: 561
Q99487 h r 314 Platelet-activating factor SID: 7195 1-alkyl-sn-glycero-3-phosphocholine SID: 6975
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Table 2 34 proteins with active site nsSNV with substrate/product/pathway relationships ideal for use in metabolomics (Continued)
Q9NVF9 n s 94 Ethanolamine CID: 700 Phosphoethanolamine CID: 1015
Q9P2T1 g d 242 Guanylic acid CID: 6804 Inosinic acid CID: 8582
Q9Y2Z4 g s 243 L-tyrosine CID: 6057 L-tyrosyl-tRNA(Tyr) SID: 5781
This table provides the UniProtKB accession ID, normal and variable residues, position of the variation and substrate/product pairs with PubChem IDs for 34 proteins with annotated nsSNVs at the active site. These
proteins were chosen for this study based on a one-protein, one-variation, one-substrate/product pair relationship to simplify preliminary modeling by ensuring no complex interactions for the given protein pathway.
NOTE: This table has been updated since the prior publication to include 2 additional proteins which were later identified to meet the criteria.
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similarly retrieved from KEGG and recorded. Pathway
conservation is indicated by similar pathway map with
identical substrates and products. All 6 ortholog pairs
were found to participate in the same pathways, acting
on the same substrates and yielding the same products.
Pathway information for these 6 proteins is included in
Table 4. Further support for functional similarity can
be seen in Figure 2, showing evidenced interactions
(collected and curated following guidance by Lim et. al.
[37] with other proteins and the distribution of func-
tional human-yeast orthologs predicted by Isobase [38]
among these subsets. A summary schema of the overall
method used in identification of these 6 candidate pro-
teins is presented in Figure 3.
Yeast 7.0 COBRA modeling
Five of the six identified candidate enzymes were input
into the Yeast 7.0 model available at http://pathway.yeast-
genome.org/ [17]. Yeast methylthioribulose-1-phosphate
dehydratase (MDE1), P47095, had no corresponding gene
in the model and was therefore excluded from this ana-
lysis. When knockouts are generated in these genes, they
all show normal growth rates except ribose-5-phosphate
isomerase (RPIA),Q12189, which showed no growth.
However, Yeast 7.0 is not equipped to predict growth
for all of these reactions because some important com-
pounds and cofactors are not currently accounted for
in the model. Findings are summarized in Table 5. (Full
output available in Additional file 1: Table A3).
Modified yeast 7.0 modeling with updated biomass function
Under the consideration that a modeling tool with a more
comprehensive biomass function could provide more
information, we repeated modeling of the 5 relevant
enzymes using a biomass function with added require-
ments for ferroheme b and charged tRNA(Tyr) in the
mitochondrion. This model was able to implicate three
additional proteins with function in essential reactions:
delta-aminolevulinic acid dehydratase (ALADH), P05373;
mitochondrial ferrochelatase, P16622; and mitochondrial
tyrosine-tRNA ligase, P48527. This additional examin-
ation, in conjunction with sequence and pathway con-
servation, supports our argument for inclusion of the
pertinent pathways in yeast cell models. A summary of
the findings can be seen in Table 5. (see Additional file 1:
Table A3 for full output).
The above Yeast 7.0 results, combined with literature
support, sequence and pathway annotations, maintain our
hypothesis that we should be able to use yeast orthologs
with active site conservation to model the effect of a vari-
ation at the active site of its human ortholog in order to
obtain a predictive overview of altered enzyme activity
resulting from the variation. Furthermore, we see the
potential for the utility of this method to improve as
advanced modeling efforts continue to progress.
Biomedical relevance
We hypothesize that nonsynonymous variation in an
enzyme’s active site should have deleterious effects on
Table 3 Conserved residues between human and yeast
orthologs at and around the active site
UniProtKB Yeast AC Human
active site
Yeast
active site
Conservation
block
P13716 P05373 221 R 232 R GDR + CYQLPP
P22830 P16622 383 D 361 D +ADLV
P48637 Q08220 125 R 128 R RSDY+
P49247 Q12189 160 D 107 D DGADEVD
Q96GX9 P47095 47 G 39 G TGTGGGIS + K
Q9Y2Z4 P48527 243 G 261 G +Q + GG + DQ
Figure 1 Manual verification of residue conservation at the active site in both human and yeast orthologs. This is the reciprocal best
BLAST hits alignment using yeast protein P05373, Delta-aminolevulinic acid dehydratase for S. cerevisiae, as the query searching against the entire
human proteome. The only human hit is P13716, also delta-aminolevulinic acid for H. sapiens. From genbank annotations, we know the active site
should occur at position 221 in the human sequence, corresponding to position 232 in the yeast sequence. Here we see conservation not only
among the active site residues, but also in the surrounding region, which can also be important in facilitating active site binding.
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the enzyme’s activity and function. Although only one of
the six human enzyme SNPs has a direct link to the On-
line Mendelian Inheritance in Man® database (OMIM®)
[41] in dbSNP (rs28936396 in P48637, human glutathione
synthetase linked to OMIM 266130 – Glutathione syn-
thetase deficiency), all six have literature related to
dysfunction and disease caused by variants found at
other positions within the protein sequence. If our as-
sumptions regarding active site variation are correct,
then nsSNVs at the active site of enzymes involved in
metabolic syndromes will likely alter protein function
and contribute to similar syndromes. Furthermore,
yeast orthologs for these enzymes with strong pathway
and active site conservation may be used to verify the
metabolic effects of such variation with respect to me-
tabolite concentrations. Although the current Yeast 7.0
model supports this hypothesis for RPIA alone, we
argue for inclusion of the pathways and metabolites asso-
ciated with these proteins in future yeast models based on
consideration of the augmented model findings, literature
and conservation among orthologs. Thus, we present five
potential disease-related proteins with active site nsSNVs
(along with yeast orthologs) in need of laboratory experi-
mentation to validate the veracity of disease related to the
SNV.
Human P49247/Yeast Q12189
Ribose-5 phosphate isomerase (RPI) participates in the
pentose phosphate pathway (PPP), an alternative pathway
for glucose oxidation accounting for up to 20% of glucose
oxidation in normal tissue. [42] Synthesis of ribose
5-phosphate from ribulose 5-phosphate via RPI is re-
quired for nucleotide and nucleic acid synthesis, and
participates in the downstream production of glycolytic
intermediates [43]. With reduced RPI activity, ribose
5-phosphate becomes unavailable and the necessary
glycolytic metabolites are not produced. Enzyme defi-
ciency results in clinical symptoms of leukoencephalopa-
thy and peripheral polyneuropathy. The RPIA gene has
also been identified to be hypermethylated at CpG sites in
breast cancer [44].
As of 2004, RPI was only the second known inborn
error in the reversible portion of the PPP [45]; the PPP
connects pentose phosphates to glycolytic intermediates.
Furthermore, there are currently only 2 mutations listed
in the Human Gene Mutation Database [46] (accessed
8/22/13) for the RPIA gene, neither of which is the
aspartic acid to tyrosine variation at active site position
160 reported here (rs11549730). RPI has been observed
to be variably conserved among species ranging from
52% similarity between human and E. coli to strong con-
servation noted between human and other mammals [47]
and RKI1 disruption has been shown to be deleterious to
yeast growth [48].
Human P13716/Yeast P05373
Delta-aminolevulinic acid dehydratase (ALADH), encoded
by the ALAD gene in humans, catalyzes the first common
step in heme and other tetrapyrrole biosynthesis [49] and
has also been observed to interact with the proteasome
Table 4 Pathway comparison between human candidate proteins and yeast orthologs using KEGG pathway
annotations
Human UniProt Ac Gene name Pathways Yeast
UniProt Ac
Yeast gene
name
Pathway
match?
Details
P13716 ALAD Porphyrin and clorophyll
metabolism
P05373 HEM2 Yes Same
Biosynthesis of secondary
metabolites
No Pathway only annotated in
yeast; same substrate/product
P22830 FECH Porphyrin and clorophyll
metabolism
P16622 HEM15 Yes Same
Biosynthesis of secondary
metabolites
No Pathway only annotated in
yeast; same substrate/product
P48637 GSS Glutathione metabolism Q08220 GSH2 Yes Same
P49247 RPIA Pentose phosphate pathway Q12189 RKI1 Yes Same
Biosynthesis of secondary
metabolites
No Pathway only annotated in
yeast; same substrate/product
Q96GX9 APIP Cysteine and methionine
metabolism
P47095 MDE1 Yes Same
Q9Y2Z4 YARS2 Aminoacyl-tRNA biosynthesis P48527 MSY1 Yes Same
This table summarizes the pathway involvement of the six identified candidate proteins. For all 6 proteins, the primary pathway involvement is the same, down to
the same products and substrates and the same place within a pathway. For three of the yeast proteins, however, the pathway annotation in KEGG listed an
additional pathway not annotated for humans: “Biosynthesis of secondary metabolites.” This is likely due to differential annotation between yeast and humans
within KEGG. Because the substrates and products annotated for these pathways were identical to those of the primary pathways, these three proteins were not
excluded and went onto analysis in the yeast FBA modeling.
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[50]. The wild-type enzyme exists as a high-activity homo-
octamer, but alternative lower-activity hexamer assemblies
have been found [51]. In fact, naturally occurring ALAD
porphyria-associated human variants have been shown to
have an increased susceptibility to hexamer-stabilizing in-
hibitors. Lead-poisoning is also hallmarked by reduced
ALAD activity. 5-aminolevulinate accumulates as a result
of the lowered activity and is responsible for the toxic
effects observed in both disease states. It has been sug-
gested that small molecule stabilization of alternate oligo-
mers (morpheeins) can be used as a therapy to target
delta-aminolevulinic acid dehydratase [52], in addition to
human immunodeficiency virus integrase, tumor necrosis
factor α, mammalian ribonucleotide reductase and other
disease-related proteins for which there is evidence of
alternate, functionally differential oligomers [53].
Figure 2 Similar protein interactions between human and yeast counterparts. Known and predicted protein interactions were retrieved
from IntAct [39] and BioGrid [40] using both human and yeast gene names as query terms. Interactions were organized and edited following
suggestions by Lim et al. [37]. It is interesting to note that although a sizeable portion of predicted interactors are also predicted to have
functional orthology between species, very few of the inter-protein interactions among predicted orthologs were reported for both species.
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Table 5 Summary of FBA results
Human Yeast Reaction tested Yeast 7.0 results
Knock-out growth Explanation
P13716 P05373 Porphobilinogen synthesis No FBA growth Ferroheme b + Yeast 7.0 biomass equation
P22830 P16622 Protoheme ferrochelatase No FBA growth Ferroheme b + Yeast 7.0 biomass equation
P48637 Q08220 Glutathione synthesis WT growth (μ = 0.1405 hr−1) 0 flux through reaction in WT (r_0485)
P49247 Q12189 Ribose-5-phosphate isomerization No FBA growth Phosphoribosyl-pyrophosphate block
Q96GX9 P47095 Methylthioribulose 1-phosphate dehydratase Not determined Gene not present in Yeast 7.0 model
Q9Y2Z4 P48527 Mitochondrial tyrosine-tRNA-ligase reaction No FBA growth Mitochondrial tRNA requirement + Yeast
7.0 biomass equation
P47095 impact could not be modeled as the Yeast 7.0 model contains no corresponding gene.
Figure 3 Schema of identification of candidate proteins for yeast modeling. The overall method used in this paper was manually
performed, but consists of simple steps and queries which could easily be automated for the performance of future similar studies.
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Mutants in the corresponding yeast HEM2 gene have
been found to disrupt heme biosynthesis, requiring
provision of heme for growth in culture [54]. Yeast and
human ALADH differ with respect to Zn cofactor binding,
thus care is required to ensure homology models account
for this difference in stoichiometry [55]. However, compari-
son of primary sequences across a diverse array of species
shows a strong degree of similarity in the region of the
active site and a zinc-binding motif [56].
There are many studies discussing ALAD-porphyria
associated mutations [57,58] but responsibility for the
disease state has not yet been assigned to the deletion
at nucleotide position 843. Interestingly, this deletion
in the active site codon also results in a frameshift, fur-
ther complicating comprehension of potential disease
mechanism(s).
Human P22830/Yeast P16622
Encoded by the FECH gene, ferrochelatase is the final
enzyme in heme biosynthesis, catalyzing the formation
of protoheme IX from protoporphyrin IX and ferrous
iron [59]. Ferrocheletase is important to human health
due to the critical and diverse functions of its product
cofactor, heme. Defects in this enzyme have been related
to erythropoietic protoporphyria (EPP). EPP is a relatively
benign disease with predominant manifestation of photo-
sensitivity, although it has been reported with liver
complications in 2-5% of patients [60]. Biological find-
ings include elevated concentrations of protoporphyrin
in erythrocytes, plasma and feces, and a large amount
of protoporphyrin in the skin [61].
Comparisons between ferrochelatases of multiple spe-
cies reveal the proteins belonging to human, mouse,
chicken, frog and Drosophila melanogaster to be metal-
loenzymes with a [2Fe-2S] cofactor, thought to play a
structural stabilizing role in humans [62]. The corre-
sponding bacteria, yeast and plant proteins contain no
iron-sulfur center, but the ferrochelatase from S. cerevisiae
is similar in other respects to eukaryotic ferrochelatases.
Yeast mutants with total or partial FECH activity defi-
ciency and resultant protoporphyrin accumulation have
been isolated [63].
Human Q9Y2Z4/Yeast P48527
Aminoacyl-tRNA synthetases (ARSs) catalyze the linkage
of specific amino acids to their cognate tRNAs [64].
Mitochondrial tyrosyl-tRNA synthetase (TyrRS) is re-
sponsible for charging tyrosine to its tRNA. Although
belonging to class I synthetases, tRNA recognition
occurs in a way more common to class II ARSs [65].
Defects in TyrRS are associated with myopathy with
lactic acidosis and sideroblastic anemia 2 (MLASA2).
It has been proposed that diminished aminoacylation
activity of the enzyme leads to decreased mitochondrial
protein synthesis and mitochondrial respiratory chain
dysfunction [66]. TyrRS also has known involvement
with cell-signaling [67] and angiogenesis [68]. Although
there are multiple known disease-related TyrRS mutants,
it is unclear for some mutants whether pathogenicity
results from dysfunction in aminoacylation or cytokine
activation.
Alignments with TyrRSs from several species reveals
34% identity with yeast and similarly low identity across
the board, with greatest conservation confined to the
N-terminus [69]. Gly-244 and Asp-246 are conserved
among class I synthetase catalytically important residues,
but a total of 8 residues are known to participate in hydro-
gen bonding [70].
Human Q96GX9/Yeast P47095
Methylthioribulose-1-phosphate dehydratase, encoded by
the APIP (APAF1-interacting protein) gene, catalyzes the
dehydratase step of the methionine salvage pathway,
converting methylthioribulose-1-phosphate into 2,3 diox-
omethylthiopentane-1-phosphate [71]. The methionine
salvage pathway recycles sulfur metabolites by recovery
of methionine from methylthioadenosine (MTA). This
pathway plays a critical role in many biological functions
including apoptosis, inflammation and cancer [72].
APIP is highly expressed in skeletal muscle and known
for an anti-apoptotic role [73]. One common APIP SNP
was observed to reduce enzyme activity, resulting in an
increase in cell death in response to Salmonella [74].
Currently excluded from the Yeast 7.0 model, the
MDH1 enzyme is of critical importance to the pathway.
Loss of function leaves the cell with no isozymes for
methionine salvage, as demonstrated in the YeastCyc
pathway/genome database (PGDB) within BioCyc [75].
The enzyme and the entire methionine salvage pathway
seem to be functionally conserved in yeast [76] and should
therefore serve as an adequate model in yeast experimen-
tation to validate predicted loss of function due to the
contained nsSNV.
Conclusions
The method proposed by this series of studies can be
generalized to identify all proteins affected by variation
at functionally important residues, to determine the
availability of orthologous yeast proteins to model the
effects of such variation and, in the future, to predict
and quantify cellular and potentially organismal responses
to the variation. The specific analyses presented here for
demonstration of the method further demonstrate that
nonsynonymous single nucleotide variation at the active
site should disrupt enzyme function and potentially in-
duce disease in yeast. However, to fully and confidently
extrapolate this finding to humans, disruption of enzyme
function must be checked against the effects of zygosity.
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This is currently a limitation imposed by existing data due
to the lack of relevant frequency information for the ma-
jority of the variations studied. We have provided 6 sets of
human/yeast enzyme ortholog pairs for which the human
protein has been experimentally shown with nsSNV at the
active site and the yeast enzyme has been verified to share
important conserved properties. Each of these enzymes is
known to have deleterious effects on human physiology
when dysfunctional, but the loss of function has been
directly related in OMIM to only one of the active site
variants, glutathione synthetase. Thus, we present five
viable candidates for variant-related disease discovery.
Preliminary FBA modeling shows predictive support for
one of these enzymes, ribose-5-phosphate isomerase.
Experimental validation of these and similar findings
will continue to increase the knowledge universe, in
turn facilitating the development of more powerful, robust
models. Advances in the technology employed by this
method may enable the long-term creation of metabolite
profiles associated with active site variation for corre-
sponding human and yeast orthologs. Simple biochemical
assays comparing human and yeast metabolite concentra-
tions to the profiles could facilitate detection of active site
non-synonymous variation. This may further lay the
foundation for future diagnostic pipelines to predict
unknown outcomes of active site nsSNVs in these and
other enzymes.
Methods
Datasets and annotated information
Proteomes and all protein subsets were retrieved from
UniProtKB/Swiss-Prot (UniProt release 2012_06 [28]. nsSNV
data were extracted from UniProtKB/Swiss-Prot, dbSNP
(build 135) [29], COSMIC (version 59) [77] and NCI 60 [78]
(accessed June 28, 2012). The SNVDis tool (https://hive.bio-
chemistry.gwu.edu/snpdis.cgi?cmd=dmSnpdis) [12] was used
to retrieve the set of all proteins with nsSNVs at the active
site (as annotated by UniProtKB/Swiss-Prot or CDD). Path-
way information was retrieved from Kyoto Encyclopedia
of Genes and Genomes (KEGG) [79] using the Protein
Analysis Through Evolutionary Relationships (PANTHER)
Classification System [80]. Substrate, product and disease
information was gathered manually from KEGG and
UniProtKB/Swiss-Prot. Official names and PubChem
[81] Compound IDs (CIDs) for compounds with
specific chemical structures, or Substance IDs (SIDs) for
those without, were recorded for all substrates and
products.
Analysis
Reciprocal best BLAST hits method
Stand-alone BLAST (version 2.2.27+) [82]was downloaded
from the NCBI website. The yeast (S. cerevisiae) proteome
was downloaded from Uniprot by using the term “Baker's
yeast [559292]” for the field of Organism[OS], combined
with the term “Complete proteome”’ in the Keyword field.
The set of 559 previously selected human proteins was
retrieved from Uniprot/Swis-protKB in batch mode using
the corresponding accession numbers.
The yeast proteome file was indexed as the database,
and the human protein dataset was used as the query for
the nucleotide-to-nucleotide Blastn algorithm with all
default parameters and E-value higher than 10−5. The
customized script was developed to extract best hits
from the Blastn result. All the yeast proteins that met the
criteria were batch-retrieved from UniprotKB/Swiss-prot
by accession numbers and prepared for the opposite
direction BLAST. Reciprocal best BLAST hits method
was then accomplished by using the selected yeast pro-
teins as the query set to align against the indexed human
proteome database downloaded from Uniprot following
the similar method described above. A human-yeast
ortholog table was generated via a customized script pars-
ing the two-way BLAST results. Thus, only those proteins
which are mutual best hits with p-value higher than 10−5
were marked as the ortholog.
Manual identification of orthologous pairs
Manual examination of BLAST alignment results was
performed to verify residue conservation at and around
the active site, as well as exclusion of proteins with add-
itional homologs. Residue conservation was observed for
all 6 candidate enzymes and reported as the longest con-
tinuous sequence conservation block containing the active
site residue. Confirmation of active site annotation across
species was achieved by consulting relevant databases.
Manual confirmation of single-best-match orthologs was
done by visual verification of BLAST results of corre-
sponding human and yeast proteins performed separately
with human and yeast as query species.
FBA procedures
COBRA simulations of the Yeast 7.0 genome-scale model
were performed using Yeast 7.0.0 in the COBRA Toolbox
5.0.0 within MATLAB R2010a. In order to simulate the
effects of knocking out genes YGL040C, YOR176W, and
YPL097W, we added small (0.0005 mmol/gCDW/hr) re-
quirements for ferroheme b and charged tRNA(Tyr) in
the mitochondrion to the Yeast 7.0 biomass function,
creating an augmented biomass function. Experimental
evidence for these deletions drawn from the Saccharomy-
ces Genome Database [83] suggests that YGL040C and
YOR176W null mutants are inviable in large scale surveys,
and that YPL097W mutants are deficient in respiration.
Reference growth rates for wild-type cells lacking gene
knockouts were obtained based on aerobic growth in
glucose minimal media, using both the augmented and
the original Yeast 7.0 biomass function. Additional file 1:
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Table A3 contains fluxes obtained for simulations of wild-
type cells using the augmented biomass function and are
labeled as ‘augmented_flux’, while fluxes obtained for sim-
ulations of wild-type cells using the Yeast 7.0 biomass
function are labeled as ‘7.00_flux’. Gene knockouts were
simulated by limiting flux through the reaction carried out
by the gene product in question to zero, equaling a total
loss of function for that reaction. All COBRA simulations
employed taxicab norm minimization of fluxes as de-
scribed in the documentation for the optimizeCbModel
function.
Reviewers' comments
We appreciate the reviewer’s comments from Dr. Daniel
Haft and from Dr. Igor B. Rogozin. We have revised the
manuscript according to your comments and suggestions.
Reviewer 1: Dr. Daniel Haft
Previous work by this group identified 559 human en-
zymes in which missense mutations replace an enzyme’s
active site residue in rare alleles. Of these, 34 are assigned
a single enzymatic activity rather than a panel of alternate
substrates, with the reaction belonging to a single pathway
in human as documented by KEGG. For this paper, the
collection is winnowed further, to count only those for
which bi-directional best BLAST matches between human
and yeast identify putative ortholog pairs, uncomplicated
by paralogs that could overlap in function. This stringent
filter gets the list down to six enzymes, the topic of this
paper. A tool for flux balance analysis (FBA) is available
for yeast, but not for human. Thus, for these six enzymes,
computation based on a yeast metabolic model leads to
predictions that loss of the same function in human
causes disease.
In one sense, there is no surprise here. Mutations away
from the active site already were known to cause human
disease for five of the six enzymes. Loss of the active site
residue should be no less catastrophic to function than
truncation or frameshift errors. It is possible that a het-
erozygous active site mutant could produce a currently
unrecognized form of a disease now known only for ho-
mozygotes of an incompletely inactivated enzyme, but
that is not the point of the paper. The yeast model is
haploid. Presumably, the implications are for homozygotes
of the mutant form in human.
Authors’ response: Perhaps it wasn’t clear from our
original discussion, but we agree that the haploid yeast
model is only suited to truly “model” homozygous cases.
However, we can envision potential scenarios in which a
haploid model could still provide predictive quantitative
value in assays in highly conserved pathways for loss of
function due to heterozygous mutation at active sites in
humans. We did revisit the text relevant to this issue and
modified it to improve clarity.
Furthermore, we are not claiming that homozygous
alleles are altogether too rare, in fact the journal article
we cite here (Ng PC1, Levy S, Huang J, Stockwell TB,
Walenz BP, Li K, Axelrod N, Busam DA, Strausberg RL,
Venter JC. Genetic variation in an individual human ex-
ome. PLoS Genet. 2008 Aug 15;4(8):e1000160) reports
that just under 50% of all nonsynonymous SNPs in
HuRef are homozygous. However, they go on report that
only about 15% are likely to affect protein function in a
deleterious way and in this case, heterozygous nsSNPS
are two times more likely than homozygotes to be pre-
dicted to affect protein activity. Similarly, rare nsSNPS
are twice as likely as common nsSNPs to affect protein
function. Thus, at the active site and other functionally
important residues, protein-affecting SNPs should be
selected against and should be less likely to be observed
in homozygote form.
At your suggestion, we conducted a new PubMed
search and were able to find an article identifying a
homozygous mutation in the catalytic domain of the
MMP2 gene in two sisters with Winchester syndrome
(Rouzier C1,Vanatka R, Bannwarth S, Philip N, Coussement
A, Paquis-Flucklinger V, Lambert JC. A novel homozygous
MMP2 mutation in a family with Winchester syndrome.
Clin Genet. 2006 Mar;69(3):271–6.) The long-term com-
bination of (1) improved classification and annotation of
variation data and (2) simple increase in available studies
should allow us to find these cases and truly study the
quantitative differences of heterozygous and homozygous
states, ultimately helping to develop and refine possible de-
tection assays.
The surprising finding, actually, seems to be that even
under the stringent filtering used – conserved orthologs
from yeast to human of enzymes in a conserved path-
way – five of the six genes nominated for study are
associated with described human genetic diseases, not
simply non-viability. The alleles responsible for the
genetic disorders seen in patients may encode enzymes
that retain some residual function, probably more than
an active site mutant retains, allowing for viability.
Rather than presenting a new method to find previously
unrecognized human genetic disease, this paper forms
a field test of the bioinformatics infrastructure one
would need for such a pipeline in the future. If FBA is
not yet available for human cells, the yeast model can
stand in for a few validated human/yeast orthologs.
When it turns out that zeroing activity of several genes
causes no change, it suggests the FBA model needs re-
pair. The authors describe making such repairs, on
their way to completing their proof-of-principle for
notion that a yeast metabolic model, and an infrastruc-
ture for data integration, could point the way to the
prediction of diseases that could be caused by certain
missense mutations.
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Authors’ response: Thank you very much for your
detailed comments and review which helped us to focus
our editing efforts and improve our arguments.
Reviewer 2: Dr. Igor B. Rogozin
The authors analyzed nonsynonymous single nucleotide
variations (nsSNVs) in active site residues in human-yeast
protein alignments. This is a promising approach. I do not
see major methodological problems. The only problem
that I see is a discussion about "loss of function via
haploinsufficiency or dominant negative phenotypes". I
understand that this is a complex problem. For example,
the vast majority of disease-associated mutations in the
RPE65 gene (Poliakov E, Gubin AN, Stearn O, Li Y,
Campos MM, Gentleman S, Rogozin IB, Redmond TM.
Origin and evolution of retinoid isomerization machinery
in vertebrate visual cycle: hint from jawless vertebrates.
PLoS One. 2012;7: e49975) are recessive mutations. How-
ever a dominant mutation was recently found in this gene.
This and many other examples (including those described
in the paper) suggest that the problem of dominant muta-
tions is extremely complex. I am not sure that the fraction
of such mutations is high although I am not aware of such
estimate in active site residues.
Authors’ response: Thank you for your positive comments
regarding our approach and your general suggestions as
well. We do realize the complexity of this issue and the
necessity of exercising caution when applying models across
organisms without knowing the full characterization of the
deleterious outcome. As I mentioned in my response to Dr.
Haft above, we have discussed the issue of zygosity, pheno-
type and loss-of-function both prior to the initial submission
and since receipt of your responses. We do not want to ig-
nore the modeling ramifications of differential ploidy, but
we also don’t want to exclude candidate proteins from
downstream quantification steps as it may be possible that
future in vivo assays (developed as a product of the broader
study) can still have some impact on heterozygous disease
states even if in silico models cannot properly simulate
them. We have carefully reread and edited these sections in
response to your comments and we feel that we have clari-
fied our reasons for our treatments of these issues.
Reviewer 3: Dr. I. King Jordan
This reviewer provided no comments for publication.
Additional file
Additional file 1: Table A1. SNVDis Results (duplicates removed).
Results from initial SNVDis computation listing 934 SNPs found in
annotated human active sites. Table A2. Recip. BLAST findings. Four
column table: A – human uniprot accession; B – yeast best match to
human protein from A in BLAST; C – human best match to yeast protein
from B; D – yes if columns A and C match implying human and yeast
proteins are reciprocal best matches and can therefore be considered for
orthology. Table A3. Yeast 7.0 Outputs. Raw outputs from original and
augmented Yeast 7.0 models.
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